Macugen: more efficacious when used early in AMD?
May 1st 2006Until recently, treatment options for neovascular (wet) AMD have been limited. Thermal laser photocoagulation - a destructive mode of therapy - was indicated in a minority of neovascular cases, including extrafoveal and some cases of juxtafoveal choroidal neovascularization (CNV). Photodynamic therapy with verteporfin (PDT) marked a new era in the treatment of exudative AMD, since subfoveal lesions were no longer excluded from treatment. However, it remains that not all lesions are eligible for treatment and the beneficial effect of PDT has only been clearly evident in predominantly classic lesions.
German Society of Ophthalmology
May 1st 2006The DOG (Deutsche Ophthalmologische Gesellschaft) was founded in 1857 when a group of like-minded ophthalmologists, brought together by Albrecht von Greafe, met in Heidelberg to discuss the latest developments in their profession. This first meeting was organized to take place a few days before the international ophthalmology conference in Brussels with the idea that they would then travel on together to attend. In all, twelve people arrived in Heidleberg, where discussion topics ranged from the use of compression bandages to glaucoma treatment. It was considered such a success that they agreed to meet again the following year.
The Italian Refractive Surgery Society
April 1st 2006Earlier this year, Ophthalmology Times Europe caught up with two admirable people: the President of SICR, Roberto Pinelli and his friend and SICR colleague, Paolo Fazio. We spoke about refractive surgery practice, education and patient management and heard how both men plan to change the way that their industry is perceived and the way that it is practiced through their new society. Please go to page 19 to find out exactly what they are planning. Meanwhile, here's a snippet of information on the society to get you started.
New pharmacological options for AMD
April 1st 2006In an exciting time for the treatment of patients with exudative age-related macular degeneration, several new pharmaceutical options are being tested. Most compounds target vascular endothelial growth factor (VEGF), which is implicated in the proliferation of choroidal neovascularization. However, the effects of VEGF can be blocked at different levels.